Pete Caruso (@petecaruso.bsky.social)

Sjogren's Disease News: Nipocalimab investigational treatment has been granted FDA breakthrough therapy designation and Fast Track designation. Nipocalimab is a fully human mAb that targets the neonatal crystallizable fragment receptor (FcRn). #Sjogrens www.jnj.com/media-center...

loading . . .

Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren’s disease, has now receive... Sjögren’s disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This marks t... https://www.jnj.com/media-center/press-releases/nipocalimab-the-first-and-only-investigational-treatment-to-be-granted-u-s-fda-breakthrough-therapy-designation-for-the-treatment-of-adults-with-moderate-to-severe-sjogrens-disease-has-now-received-fast-track-designation